WE MOVE
204 West 84th Street
New York, NY 10024
E-mail: wemove@wemove.org
wemove.org • mdvu.org

Stay Connected Research News Chat Discussion Forum Advocacy and Support Organizations Patient Meeting Calendar Movement Disorder Glossary Movement Disorders Virtual University Linkage Library
WE MOVE

Dopaminergic Agents

Dopaminergic agents are often considered first-line therapies since they typically alleviate all major features associated with RLS including restlessness, abnormal sensations, involuntary movements, and associated sleep impairment. In fact, some physicians note that the effects of such medications are so specific that patients who do not have such a response to certain dopaminergic agents (i.e., carbidopa/levodopa) may have been misdiagnosed or have an associated condition that inhibits the drug's effectiveness.

Dopaminergic agents have an inhibitory effect on abnormal movements by enhancing levels of the neurotransmitter dopamine, a naturally produced chemical that regulates the delivery of messages between nerve cells (neurons) in the central nervous system. Such medications include dopamine precursors and dopamine agonists.